Conflict of interest statement: CONFLICTS OF INTEREST P.V. received honoraria anda research grant from Ariad. All other authors declare no conflicts of interest.104. Oncotarget. 2018 May 29;9(41):26406-26416. doi: 10.18632/oncotarget.25413.eCollection 2018 May 29.Triple negative breast cancer subtypes and pathologic complete response rate toneoadjuvant chemotherapy.Santonja A(1)(2), Sánchez-Muñoz A(3)(4), Lluch A(4)(5)(6)(7), Chica-ParradoMR(1)(2), Albanell J(4)(5)(8)(9), Chacón JI(5)(10), Antolín S(5)(11), JerezJM(12), de la Haba J(4)(5)(13)(14), de Luque V(1)(2), Fernández-De SousaCE(1)(2), Vicioso L(1)(15)(16), Plata Y(17), Ramírez-Tortosa CL(18), ÁlvarezM(1)(2)(16), Llácer C(3), Zarcos-Pedrinaci I(19)(20), Carrasco E(5), CaballeroR(5), Martín M(4)(5)(21), Alba E(2)(3)(4)(5).Author information: (1)Instituto de Investigación Biomédica de Málaga (IBIMA), HospitalesUniversitarios Regional y Virgen de la Victoria, Málaga, Spain.(2)Laboratorio de Biología Molecular del Cáncer, Centro de InvestigacionesMédico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.(3)Unidad de Gestión Clínica Intercentro de Oncología, Instituto de InvestigaciónBiomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de laVictoria, Málaga, Spain.(4)Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII,Madrid, Spain.(5)Spanish Breast Cancer Research Group (GEICAM), Madrid, Spain.(6)Department of Oncology and Hematology, Hospital Clínico Universitario,Valencia, Spain.(7)INCLIVA Biomedical Research Institute, Universidad de Valencia, Valencia,Spain.(8)Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute),Medical Oncology Service, Hospital del Mar, Barcelona, Spain.(9)Universitat Pompeu Fabra, Barcelona, Spain.(10)Medical Oncology Service, Hospital Virgen de la Salud, Toledo, Spain.(11)Medical Oncology Service, Complejo Hospitalario Universitario de A Coruña, LaCoruña, Spain.(12)Department of Languages and Computer Science, Instituto de InvestigaciónBiomédica de Málaga (IBIMA), Universidad de Málaga, Málaga, Spain.(13)Medical Oncology Service, Complejo Hospitalario Reina Sofía, Córdoba, Spain.(14)The Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain.(15)Department of Pathology, Hospitales Universitarios Regional y Virgen de laVictoria, Málaga, Spain.(16)Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.(17)Department of Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.(18)Department of Pathology, Complejo Hospitalario de Jaén, Jaén, Spain.(19)Medical Oncology Service, Hospital Costa del Sol, Marbella, Málaga, Spain.(20)Health Services Research on Chronic Diseases Network - REDISSEC, Marbella,Málaga, Spain.(21)Instituto de Investigación Sanitaria Gregorio Marañón, UniversidadComplutense de Madrid, Madrid, Spain.Triple negative breast cancer (TNBC) is a heterogeneous disease with distinctmolecular subtypes that differentially respond to chemotherapy and targetedagents. The purpose of this study is to explore the clinical relevance of LehmannTNBC subtypes by identifying any differences in response to neoadjuvantchemotherapy among them. We determined Lehmann subtypes by gene expressionprofiling in paraffined pre-treatment tumor biopsies from 125 TNBC patientstreated with neoadjuvant anthracyclines and/or taxanes +/- carboplatin. Weexplored the clinicopathological characteristics of Lehmann subtypes and theirassociation with the pathologic complete response (pCR) to different treatments. The global pCR rate was 37%, and it was unevenly distributed within Lehmann'ssubtypes. Basal-like 1 (BL1) tumors exhibited the highest pCR to carboplatincontaining regimens (80% vs 23%, p=0.027) and were the most proliferative(Ki-67>50% of 88.2% vs. 63.7%, p=0.02). Luminal-androgen receptor (LAR) patients achieved the lowest pCR to all treatments (14.3% vs 42.7%, p=0.045 when excludingmesenchymal stem-like (MSL) samples) and were the group with the lowestproliferation (Ki-67≤50% of 71% vs 27%, p=0.002). In our cohort, only tumors withLAR phenotype presented non-basal-like intrinsic subtypes (HER2-enriched andluminal A). TNBC patients present tumors with a high genetic diversity rangingfrom highly proliferative tumors, likely responsive to platinum-based therapies, to a subset of chemoresistant tumors with low proliferation and luminalcharacteristics.DOI: 10.18632/oncotarget.25413 PMCID: PMC5995183PMID: 29899867 